All In MedTech

Device Trial Radar · NCT04096391

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population (PROSPER)

Last checked: Nov 20, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Jun 5, 2019

Primary completion

Apr 11, 2022

Study completion Apr 11, 2022

Sponsor

Lead sponsor
Evolve Restorative CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Flowonix Medical; Celéri Health, Inc.; Advanced Infusion Solutions
First posted
Sep 19, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to compare intrathecal morphine using the commercially available intrathecal drug delivery systems (IDDS), and conventional medical management (CMM) in subjects with non-cancer, refractory chronic pain.

Conditions

  • Chronic Nonmalignant Pain
  • Pain, Intractable
  • Pain, Chronic

Interventions

  • Flowonix Prometra® II Programmable Infusion SystemDevice

    The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).

  • Pain MedicineDrug

    Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the change in Numeric Pain Rating Scale between the IDDS group and the CMM groupTime frame: Comparisons will be done prior to baseline visit and at 3, 6, 9 and 12 month visits.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Evolve Restorative Center

    Santa Rosa, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.